Gastroparesis remains one of the most underdiagnosed and poorly understood motility disorders affecting the digestive tract, yet its consequences — chronic nausea, vomiting, malnutrition, and dramatically reduced quality of life — are anything but subtle. A comprehensive narrative review in JAMA synthesizes what is now known about this condition across its full clinical arc, offering clinicians and informed patients a consolidated framework for understanding why the stomach fails to empty properly and what can realistically be done about it.
The review covers the multifactorial pathogenesis of gastroparesis, which extends well beyond the classic association with diabetic autonomic neuropathy. Interstitial cells of Cajal — the pacemaker cells of gut motility — appear to be depleted in a significant subset of patients, alongside evidence of smooth muscle fibrosis and immune-mediated inflammation at the enteric nervous system level. Epidemiologically, the condition disproportionately affects women and those with longstanding diabetes, though idiopathic cases constitute a substantial proportion of diagnoses. Diagnostic standards still center on gastric emptying scintigraphy at four hours, though wireless motility capsule technology is gaining traction as an alternative. Treatment approaches range from dietary modification and prokinetic agents to gastric electrical stimulation and, in refractory cases, surgical intervention.
What makes this review clinically valuable is its attempt to reconcile a fragmented literature. Gastroparesis has long suffered from a shortage of large, well-controlled trials — most pharmacological evidence derives from small cohorts or short-duration studies, limiting confidence in treatment algorithms. The inclusion of prognostic data is particularly useful: outcomes are highly variable and strongly tied to underlying etiology, with diabetic gastroparesis showing potential for improvement when glycemic control is optimized. For a health-conscious readership, the key takeaway is that unexplained upper GI symptoms persisting beyond weeks warrant formal motility evaluation — gastroparesis is more prevalent than commonly assumed and remains significantly underdiagnosed in primary care settings.